Clinical characteristics of cGVHD in the study population
| . | Mild . | Moderate . | Severe . | Resolved . |
|---|---|---|---|---|
| N = 15 . | N = 14 . | N = 9 . | N = 12 . | |
| Mucosal, oral and/or genital (%) | 8 (53) | 11 (78) | 7 (77) | |
| Scleroderma (%) | 0 | 3 (21) | 3 (33) | |
| Lung (%) | 0 | 0 | 5 (55) | |
| Immunosuppressive therapy at sample collection (%) | 7 (47) | 10 (71) | 7 (77) | 1 (8) |
| Steroid treatment (%) | 5 (33) | 5 (35) | 6 (66) | 0 |
| Mean steroid dose, mg/kg/d | 0.108 | 0.142 | 0.276 | 0 |
| Mean time between resolution and sample collection, mo | — | — | — | 28.9 |
| . | Mild . | Moderate . | Severe . | Resolved . |
|---|---|---|---|---|
| N = 15 . | N = 14 . | N = 9 . | N = 12 . | |
| Mucosal, oral and/or genital (%) | 8 (53) | 11 (78) | 7 (77) | |
| Scleroderma (%) | 0 | 3 (21) | 3 (33) | |
| Lung (%) | 0 | 0 | 5 (55) | |
| Immunosuppressive therapy at sample collection (%) | 7 (47) | 10 (71) | 7 (77) | 1 (8) |
| Steroid treatment (%) | 5 (33) | 5 (35) | 6 (66) | 0 |
| Mean steroid dose, mg/kg/d | 0.108 | 0.142 | 0.276 | 0 |
| Mean time between resolution and sample collection, mo | — | — | — | 28.9 |